biostudies-literatureKwon JHNCATS NIH HHSCenters for Disease Control and PreventionClinical and Translational Science AwardNIGMS NIH HHSCDC HHS797-807https://www.ebi.ac.uk/biostudies/studies/S-EPMC9047160biostudies-literatureUnknown226(5)<h4>Background</h4>The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients.<h4>Methods</h4>We conducted a 21-site case-control analysis of 10 425 adults hospitalized in March to December 2021. Cases were hospitalized with COVID-19; controls were hospitalized for an alternative diagnosis (severe acute respiratory syndrome coronavirus 2-negative). Participants were classified as follows: SOT recipient (n = 440), other immunocompromising condition (n = 1684), or immunocompetent (n = 8301). The VE against COVID-19-associated hospitalization was calculated as 1-adjusted odds ratio of prior vaccination among cases compared with controls.<h4>Results</h4>Among SOT recipients, VE was 29% (95% confidence interval [CI], -19% to 58%) for 2 doses and 77% (95% CI, 48% to 90%) for 3 doses. Among patients with other immunocompromising conditions, VE was 72% (95% CI, 64% to 79%) for 2 doses and 92% (95% CI, 85% to 95%) for 3 doses. Among immunocompetent patients, VE was 88% (95% CI, 87% to 90%) for 2 doses and 96% (95% CI, 83% to 99%) for 3 doses.<h4>Conclusions</h4>Effectiveness of COVID-19 mRNA vaccines was lower for SOT recipients than immunocompetent adults and those with other immunocompromising conditions. Among SOT recipients, vaccination with 3 doses of an mRNA vaccine led to substantially greater protection than 2 doses.The Journal of infectious diseasesmRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients.PMC9047160UL1 TR002243K23 GM12966175D30121F00002T32 GM135169Rovinski RMohr NMExline MCRice TWGhamande SBaughman AChang SYKobayashi MZepeski AMartin ETWilson JGBrown SMWomack KNSelf WHShehu AHalasa NSchrag SSteingrub JSBabcock HMFelley LJohnson NJHough CLDouin DJGinde AAMcNeal TLauring ASHager DNCaspers SDCasey JDBusse LWKwon JHTalbot HKChappell JDLindsell CJOlson SMGibbs KWGaglani MVerani JRTenforde MWHart KWShapiro NIPerez CMallow CLi APatel MMSrinivasan VGong MNGrijalva CGPeltan IDMohamed AKhan APrekker MEBotros MFiles DCDuggal AfalsemRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients.<h4>Background</h4>The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients.<h4>Methods</h4>We conducted a 21-site case-control analysis of 10 425 adults hospitalized in March to December 2021. Cases were hospitalized with COVID-19; controls were hospitalized for an alternative diagnosis (severe acute respiratory syndrome coronavirus 2-negative). Participants were classified as follows: SOT recipient (n = 440), other immunocompromising condition (n = 1684), or immunocompetent (n = 8301). The VE against COVID-19-associated hospitalization was calculated as 1-adjusted odds ratio of prior vaccination among cases compared with controls.<h4>Results</h4>Among SOT recipients, VE was 29% (95% confidence interval [CI], -19% to 58%) for 2 doses and 77% (95% CI, 48% to 90%) for 3 doses. Among patients with other immunocompromising conditions, VE was 72% (95% CI, 64% to 79%) for 2 doses and 92% (95% CI, 85% to 95%) for 3 doses. Among immunocompetent patients, VE was 88% (95% CI, 87% to 90%) for 2 doses and 96% (95% CI, 83% to 99%) for 3 doses.<h4>Conclusions</h4>Effectiveness of COVID-19 mRNA vaccines was lower for SOT recipients than immunocompetent adults and those with other immunocompromising conditions. Among SOT recipients, vaccination with 3 doses of an mRNA vaccine led to substantially greater protection than 2 doses.2022-01-01T00:00:00Z2022 Sep2024-11-12T11:48:42.529Z2024-11-12T11:48:42.529ZS-EPMC90471603538587510.1093/infdis/jiac118